ArticleDermatology and therapy2024

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).

Eric L Simpson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.